{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:36:23Z","timestamp":1790246183425,"version":"4.1.0"},"reference-count":45,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Two major immunologic barriers, the host-versus-graft (HVG) and graft-versus-host (GVH) reactions, have to be overcome for successful allogeneic hematopoietic cell transplantation. T cells were shown to be primarily involved in these barriers in the major histocompatibility complex identical setting. We hypothesized that selective ablation of T cells using radioimmunotherapy together with postgrafting immunosuppression would suffice to ensure stable allogeneic engraftment. We had described a canine model of nonmyeloablative marrow transplantation in which host immune reactions were impaired by a single dose of 200 cGy total body irradiation (TBI), and both GVH and residual HVG reactions were controlled by postgrafting immunosuppression with mycophenolate mofetil (MMF) and cyclosporine (CSP). Here, we substituted the \u03b1-emitter bismuth-213 (213Bi) linked to a monoclonal antibody (mAb) against T-cell receptor (TCR) \u03b1\u03b2, using the metal-binding chelate diethylenetriaminepentaacetic acid (DTPA) derivative cyclohexyl\u2013(CHX)-A\u2033, for 200 cGy TBI. Biodistribution studies using a \u03b3-emitting indium-111\u2013labeled anti-TCR\u03b1\u03b2 mAb showed uptake primarily in blood, marrow, lymph nodes, spleen, and liver. Four dogs were treated with 0.13 to 0.46 mg\/kg TCR\u03b1\u03b2 mAb labeled with 3.7 to 5.6 mCi\/kg (137-207 MBq\/kg) 213Bi. The treatment was administered in 6 injections on days \u20133 and \u20132 followed by transplantation of dog leukocyte antigen-identical marrow on day 0 and postgrafting immunosuppression with MMF\/CSP. The therapy was well tolerated except for elevations of transaminases that were transient in all but one of the dogs. No other organ toxicities or signs of graft-versus-host disease were noted. The dogs had prompt allogeneic hematopoietic engraftment and achieved stable mixed donor-host hematopoietic chimerism with donor contributions ranging from 5% to 55% after more than 30 weeks of follow up.<\/jats:p>","DOI":"10.1182\/blood-2002-12-3867","type":"journal-article","created":{"date-parts":[[2003,3,4]],"date-time":"2003-03-04T01:29:44Z","timestamp":1046741384000},"page":"5068-5075","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":57,"title":["Selective T-cell ablation with bismuth-213\u2013labeled anti-TCR\u03b1\u03b2 as nonmyeloablative conditioning for allogeneic canine marrow transplantation"],"prefix":"10.1182","volume":"101","author":[{"given":"Wolfgang A.","family":"Bethge","sequence":"first","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Medicine, University of Washington, Seattle; Department of Radiation Oncology, University of Washington, Seattle; National Cancer Institute, National Institutes of Health, Bethesda, MD; and Pacific Northwest National Laboratory, Richland, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Scott","family":"Wilbur","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Medicine, University of Washington, Seattle; Department of Radiation Oncology, University of Washington, Seattle; National Cancer Institute, National Institutes of Health, Bethesda, MD; and Pacific Northwest National Laboratory, Richland, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Storb","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Medicine, University of Washington, Seattle; Department of Radiation Oncology, University of Washington, Seattle; National Cancer Institute, National Institutes of Health, Bethesda, MD; and Pacific Northwest National Laboratory, Richland, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald K.","family":"Hamlin","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Medicine, University of Washington, Seattle; Department of Radiation Oncology, University of Washington, Seattle; National Cancer Institute, National Institutes of Health, Bethesda, MD; and Pacific Northwest National Laboratory, Richland, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erlinda B.","family":"Santos","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Medicine, University of Washington, Seattle; Department of Radiation Oncology, University of Washington, Seattle; National Cancer Institute, National Institutes of Health, Bethesda, MD; and Pacific Northwest National Laboratory, Richland, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin W.","family":"Brechbiel","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Medicine, University of Washington, Seattle; Department of Radiation Oncology, University of Washington, Seattle; National Cancer Institute, National Institutes of Health, Bethesda, MD; and Pacific Northwest National Laboratory, Richland, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrell R.","family":"Fisher","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Medicine, University of Washington, Seattle; Department of Radiation Oncology, University of Washington, Seattle; National Cancer Institute, National Institutes of Health, Bethesda, MD; and Pacific Northwest National Laboratory, Richland, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda M.","family":"Sandmaier","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Medicine, University of Washington, Seattle; Department of Radiation Oncology, University of Washington, Seattle; National Cancer Institute, National Institutes of Health, Bethesda, MD; and Pacific Northwest National Laboratory, Richland, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021222221008700_REF1","doi-asserted-by":"crossref","unstructured":"Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood. 1997;89: 3048-3054.","DOI":"10.1182\/blood.V89.8.3048"},{"key":"2020021222221008700_REF2","doi-asserted-by":"crossref","unstructured":"McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97: 3390-3400.","DOI":"10.1182\/blood.V97.11.3390"},{"key":"2020021222221008700_REF3","unstructured":"Matthews DC, Badger CC, Fisher DR, et al. Selective radiation of hematolymphoid tissue delivered by anti-CD45 antibody. Cancer Res. 1992;52: 1228-1234."},{"key":"2020021222221008700_REF4","doi-asserted-by":"crossref","unstructured":"Matthews DC, Appelbaum FR, Press OW, Eary JF, Bernstein ID. The use of radiolabeled antibodies in bone marrow transplantation for hematologic malignancies. Cancer Treat Res. 1997;77: 121-139.","DOI":"10.1007\/978-1-4615-6349-5_6"},{"key":"2020021222221008700_REF5","doi-asserted-by":"crossref","unstructured":"Sandmaier BM, Bethge WA, Wilbur DS, et al. Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. Blood. 2002;100: 318-326.","DOI":"10.1182\/blood-2001-12-0322"},{"key":"2020021222221008700_REF6","doi-asserted-by":"crossref","unstructured":"Storb R, Yu C, Barnett T, et al. Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation. Blood. 1999;94: 1131-1136.","DOI":"10.1182\/blood.V94.3.1131.415k21_1131_1136"},{"key":"2020021222221008700_REF7","doi-asserted-by":"crossref","unstructured":"Nakamura H, Gress RE. Graft rejection by cytolytic T cells: specificity of the effector mechanism in the rejection of allogeneic marrow. Transplantation. 1990;49: 453-458.","DOI":"10.1097\/00007890-199002000-00042"},{"key":"2020021222221008700_REF8","unstructured":"Bosserman LD, Murray C, Takvorian T, et al. Mechanism of graft failure in HLA-matched and HLA-mismatched bone marrow transplant recipients. Bone Marrow Transplant. 1989;4: 239-245."},{"key":"2020021222221008700_REF9","doi-asserted-by":"crossref","unstructured":"Reisner Y, Ben Bassat I, Douer D, et al. Demonstration of clonable alloreactive host T cells in a primate model for bone marrow transplantation. Proc Natl Acad Sci U S A. 1986;83: 4012-4015.","DOI":"10.1073\/pnas.83.11.4012"},{"key":"2020021222221008700_REF10","doi-asserted-by":"crossref","unstructured":"Butturini A, Seeger RC, Gale RP. Recipient immune-competent T lymphocytes can survive intensive conditioning for bone marrow transplantation. Blood. 1986;68: 954-956.","DOI":"10.1182\/blood.V68.4.954.954"},{"key":"2020021222221008700_REF11","doi-asserted-by":"crossref","unstructured":"Xu H, Exner BG, Cramer DE, et al. CD8(+), alphabeta-TCR(+), and gammadelta-TCR(+) cells in the recipient hematopoietic environment mediate resistance to engraftment of allogeneic donor bone marrow. J Immunol. 2002;168: 1636-1643.","DOI":"10.4049\/jimmunol.168.4.1636"},{"key":"2020021222221008700_REF12","doi-asserted-by":"crossref","unstructured":"Kikly K, Dennert G. Evidence for a role for T cell receptors (TCR) in the effector phase of acute bone marrow graft rejection: TCR V beta 5 transgenic mice lack effector cells able to cause graft rejection. J Immunol. 1992;149: 3489-3494.","DOI":"10.4049\/jimmunol.149.11.3489"},{"key":"2020021222221008700_REF13","doi-asserted-by":"crossref","unstructured":"Wu C, Kobayashi H, Sun B, et al. Stereochemical influence on the stability of radio-metal complexes in vivo: synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans-Cy-DTPA. Bioorg Med Chem. 1997;5: 1925-1934.","DOI":"10.1016\/S0968-0896(97)00130-2"},{"key":"2020021222221008700_REF14","doi-asserted-by":"crossref","unstructured":"McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med. 1998;25: 1341-1351.","DOI":"10.1007\/s002590050306"},{"key":"2020021222221008700_REF15","doi-asserted-by":"crossref","unstructured":"Barsoukov AA, Moore PF, Storb R, Santos EB, Sandmaier BM. The use of an anti-TCRalphabeta monoclonal antibody to control host-versus-graft reactions in canine marrow allograft recipients conditioned with low dose total body irradiation. Transplantation. 1999;67: 1329-1335.","DOI":"10.1097\/00007890-199905270-00007"},{"key":"2020021222221008700_REF16","doi-asserted-by":"crossref","unstructured":"Caniatti M, Roccabianca P, Scanziani E, Paltrinieri S, Moore PF. Canine lymphoma: immunocytochemical analysis of fine-needle aspiration biopsy. Vet Pathol. 1996;33: 204-212.","DOI":"10.1177\/030098589603300210"},{"key":"2020021222221008700_REF17","doi-asserted-by":"crossref","unstructured":"Moore PF, Rossitto PV, Danilenko DM, et al. Monoclonal antibodies specific for canine CD4 and CD8 define functional T-lymphocyte subsets and high-density expression of CD4 by canine neutrophils. Tissue Antigens. 1992;40: 75-85.","DOI":"10.1111\/j.1399-0039.1992.tb01963.x"},{"key":"2020021222221008700_REF18","doi-asserted-by":"crossref","unstructured":"Sandmaier BM, Storb R, Appelbaum FR, Gallatin WM. An antibody that facilitates hematopoietic engraftment recognizes CD44. Blood. 1990;76: 630-635.","DOI":"10.1182\/blood.V76.3.630.630"},{"key":"2020021222221008700_REF19","unstructured":"Sandmaier BM, Schuening FG, Bianco JA, et al. Biochemical characterization of a unique canine myeloid antigen. Leukemia. 1991;5: 125-130."},{"key":"2020021222221008700_REF20","doi-asserted-by":"crossref","unstructured":"Denkers EY, Badger CC, Ledbetter JA, Bernstein ID. Influence of antibody isotype on passive serotherapy of lymphoma. J Immunol. 1985;135: 2183-2186.","DOI":"10.4049\/jimmunol.135.3.2183"},{"key":"2020021222221008700_REF21","doi-asserted-by":"crossref","unstructured":"Jacobsen CN, Aasted B, Broe MK, Petersen JL. Reactivities of 20 anti-human monoclonal antibodies with leucocytes from ten different animal species. Vet Immunol Immunopathol. 1993;39: 461-466.","DOI":"10.1016\/0165-2427(93)90075-F"},{"key":"2020021222221008700_REF22","doi-asserted-by":"crossref","unstructured":"Pippin CG, Parker TA, McMurry TJ, Brechbiel MW. Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates. Bioconjug Chem. 1992;3: 342-345.","DOI":"10.1021\/bc00016a014"},{"key":"2020021222221008700_REF23","doi-asserted-by":"crossref","unstructured":"Wagner JL, Burnett RC, DeRose SA, et al. Histocompatibility testing of dog families with highly polymorphic microsatellite markers. Transplantation. 1996;62: 876-877.","DOI":"10.1097\/00007890-199609270-00032"},{"key":"2020021222221008700_REF24","doi-asserted-by":"crossref","unstructured":"Wagner JL, Works JD, Storb R. DLA-DRB1 and DLA-DQB1 histocompatibility typing by PCR-SSCP and sequencing. Tissue Antigens. 1998;52: 397-401.","DOI":"10.1111\/j.1399-0039.1998.tb03063.x"},{"key":"2020021222221008700_REF25","doi-asserted-by":"crossref","unstructured":"Sandmaier BM, Storb R, Bennett KL, Appelbaum FR, Santos EB. Epitope specificity of CD44 for monoclonal antibody-dependent facilitation of marrow engraftment in a canine model. Blood. 1998;91: 3494-3502.","DOI":"10.1182\/blood.V91.9.3494"},{"key":"2020021222221008700_REF26","doi-asserted-by":"crossref","unstructured":"Loughran TP Jr, Deeg HJ, Storb R. Morphologic and phenotypic analysis of canine natural killer cells: evidence for T-cell lineage. Cell Immunol. 1985;95: 207-217.","DOI":"10.1016\/0008-8749(85)90309-0"},{"key":"2020021222221008700_REF27","doi-asserted-by":"crossref","unstructured":"Raff RF, Deeg HJ, Farewell VT, DeRose S, Storb R. The canine major histocompatibility complex: population study of DLA-D alleles using a panel of homozygous typing cells. Tissue Antigens. 1983;21: 360-373.","DOI":"10.1111\/j.1399-0039.1983.tb00185.x"},{"key":"2020021222221008700_REF28","unstructured":"Bianco JA, Sandmaier B, Brown PA, et al. Specific marrow localization of an 131I-labeled anti-myeloid antibody in normal dogs: effects of a \u201ccold\u201d antibody pretreatment dose on marrow localization. Exp Hematol. 1989;17: 929-934."},{"key":"2020021222221008700_REF29","unstructured":"Ladiges WC, Storb R, Thomas ED. Canine models of bone marrow transplantation. Lab Anim Sci. 1990;40: 11-15."},{"key":"2020021222221008700_REF30","doi-asserted-by":"crossref","unstructured":"Yu C, Ostrander E, Bryant E, Burnett R, Storb R. Use of (CA)n polymorphisms to determine the origin of blood cells after allogeneic canine marrow grafting. Transplantation. 1994;58: 701-706.","DOI":"10.1097\/00007890-199409270-00011"},{"key":"2020021222221008700_REF31","doi-asserted-by":"crossref","unstructured":"Francisco LV, Langston AA, Mellersh CS, Neal CL, Ostrander EA. A class of highly polymorphic tetranucleotide repeats for canine genetic mapping. Mamm Genome. 1996;7: 359-362.","DOI":"10.1007\/s003359900104"},{"key":"2020021222221008700_REF32","doi-asserted-by":"crossref","unstructured":"Reichert WL, Stein JE, French B, Goodwin P, Varanasi U. Storage phosphor imaging technique for detection and quantitation of DNA adducts measured by the 32P-postlabeling assay. Carcinogenesis. 1992;13: 1475-1479.","DOI":"10.1093\/carcin\/13.8.1475"},{"key":"2020021222221008700_REF33","doi-asserted-by":"crossref","unstructured":"Appelbaum FR, Brown P, Sandmaier B, et al. Antibody-radionuclide conjugates as part of a myeloablative preparative regimen for marrow transplantation. Blood. 1989;73: 2202-2208.","DOI":"10.1182\/blood.V73.8.2202.2202"},{"key":"2020021222221008700_REF34","unstructured":"Ruffner KL, Martin PJ, Hussell S, et al. Immunosuppressive effects of 131I-anti-CD45 antibody in unsensitized and donor antigen-presensitized H2-matched, minor antigen-mismatched murine transplant models. Cancer Res. 2001;61: 5126-5131."},{"key":"2020021222221008700_REF35","doi-asserted-by":"crossref","unstructured":"Matthews DC, Appelbaum FR, Eary JF, et al. Radiolabeled anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque. Blood. 1991;78: 1864-1874.","DOI":"10.1182\/blood.V78.7.1864.1864"},{"key":"2020021222221008700_REF36","doi-asserted-by":"crossref","unstructured":"Bunjes D, Buchmann I, Duncker C, et al. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. Blood. 2001;98: 565-572.","DOI":"10.1182\/blood.V98.3.565"},{"key":"2020021222221008700_REF37","doi-asserted-by":"crossref","unstructured":"Matthews DC, Appelbaum FR, Eary JF, et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood. 1999;94: 1237-1247.","DOI":"10.1182\/blood.V94.4.1237"},{"key":"2020021222221008700_REF38","doi-asserted-by":"crossref","unstructured":"Raju MR, Eisen Y, Carpenter S, Inkret WC. Radiobiology of alpha particles, III: cell inactivation by alpha-particle traversals of the cell nucleus. Radiat Res. 1991;128: 204-209.","DOI":"10.2307\/3578139"},{"key":"2020021222221008700_REF39","doi-asserted-by":"crossref","unstructured":"Abbas Rizvi SM, Sarkar S, Goozee G, Allen BJ. Radioimmunoconjugates for targeted alpha therapy of malignant melanoma. Melanoma Res. 2000;10: 281-289.","DOI":"10.1097\/00008390-200010030-00011"},{"key":"2020021222221008700_REF40","doi-asserted-by":"crossref","unstructured":"Macklis RM, Kinsey BM, Kassis AI, et al. Radioimmunotherapy with alpha-particle-emitting immunoconjugates. Science. 1988;240: 1024-1026.","DOI":"10.1126\/science.2897133"},{"key":"2020021222221008700_REF41","unstructured":"Behr TM, Behe M, Stabin MG, et al. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi-versus 90Y-labeled CO17\u20131A Fab\u2032 fragments in a human colonic cancer model. Cancer Res. 1999;59: 2635-2643."},{"key":"2020021222221008700_REF42","doi-asserted-by":"crossref","unstructured":"Milenic DE, Roselli M, Mirzadeh S, et al. In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates. Cancer Biother Radiopharm. 2001;16: 133-146.","DOI":"10.1089\/108497801300189227"},{"key":"2020021222221008700_REF43","unstructured":"Nikula TK, McDevitt MR, Finn RD, et al. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. J Nucl Med. 1999;40: 166-176."},{"key":"2020021222221008700_REF44","doi-asserted-by":"crossref","unstructured":"Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood. 2002;100: 1233-1239.","DOI":"10.1182\/blood.V100.4.1233.h81602001233_1233_1239"},{"key":"2020021222221008700_REF45","doi-asserted-by":"crossref","unstructured":"Mehal WZ, Azzaroli F, Crispe IN. Immunology of the healthy liver: old questions and new insights. Gastroenterology. 2001;120: 250-260.","DOI":"10.1053\/gast.2001.20947"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/12\/5068\/1687836\/h81203005068.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/12\/5068\/1687836\/h81203005068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T21:19:13Z","timestamp":1682457553000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/101\/12\/5068\/17052\/Selective-Tcell-ablation-with-bismuth213labeled"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6,15]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2003,6,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-12-3867","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,6,15]]}}}